Cargando…
Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma
OBJECTIVE: To analyze the pattern of failure in relation to pre-treatment [(18)F] FDG-PET/CT uptake in head and neck squamous cell carcinoma (HNSCC) patients treated with definitive radio-chemotherapy (RT-CHT). METHODS AND MATERIALS: From 2012 to 2016, 87 HNSCC patients treated with definitive RT-CH...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981918/ https://www.ncbi.nlm.nih.gov/pubmed/33743759 http://dx.doi.org/10.1186/s13014-021-01787-5 |
_version_ | 1783667611831107584 |
---|---|
author | Pisani, C. Vigna, L. Mastroleo, F. Loi, G. Amisano, V. Masini, L. Deantonio, L. Aluffi Valletti, P. Sacchetti, G. Krengli, M. |
author_facet | Pisani, C. Vigna, L. Mastroleo, F. Loi, G. Amisano, V. Masini, L. Deantonio, L. Aluffi Valletti, P. Sacchetti, G. Krengli, M. |
author_sort | Pisani, C. |
collection | PubMed |
description | OBJECTIVE: To analyze the pattern of failure in relation to pre-treatment [(18)F] FDG-PET/CT uptake in head and neck squamous cell carcinoma (HNSCC) patients treated with definitive radio-chemotherapy (RT-CHT). METHODS AND MATERIALS: From 2012 to 2016, 87 HNSCC patients treated with definitive RT-CHT, with intensity modulated radiation therapy with simultaneous integrated boost, underwent pre-treatment [(18)F] FDG-PET/CT (PET(pre)), and MRI/CT for radiotherapy (RT) planning purposes. Patients with local recurrence, received [(18)F] FDG-PET/CT, (PET(rec)) at the time of the discovery of recurrence. In these patients, the metabolic target volume (MTV), MTV(pre) and MTV(rec) were segmented on PET images by means of an adaptive thresholding algorithm. The overlapping volume between MTV(pre) and MTV(rec) (MTV(pre&rec)) was generated and the dose coverage of MTV(rec) and MTV(pre&rec) was checked on the planning CT using the D99 and D95 dose metrics. The recurrent volume was defined as: ‘‘In-Field (IF)’’, “Marginal recurrence” or ‘‘Out-of-Field (OF)’’ if D95 was respectively equal or higher than 95%, D95 was between 95 and 20% or the D95 was less than 20% of prescribed dose. RESULTS: We found 10/87 patients (11.5%) who had recurrence at primary site. Mean MTV(pre) was 12.2 cc (4.6–28.9 cc), while the mean MTV(rec) was 4.3 cc (1.1–12.7 cc). Two recurrences resulted 100% inside MTV(pre), 4 recurrences were mostly inside (61–91%) and 4 recurrences were marginal to MTV(pre) (1–33%). At dosimetric analysis, five recurrences (50%) were IF, 4 (40%) marginal and one (10%) OF. The mean D99 of the overlapping volumes MTV(pre&rec) was 68.1 Gy (66.5–69.2 Gy), considering a prescription dose of 70 Gy to the planning target volume (PTV). CONCLUSION: Our study shows that the recurrence may originate from the volume with the highest FDG-signal. Tumor relapse in the high-dose volume support the hypothesis that an intensification of the dose on these volumes could be further assessed to prevent local relapse. |
format | Online Article Text |
id | pubmed-7981918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79819182021-03-22 Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma Pisani, C. Vigna, L. Mastroleo, F. Loi, G. Amisano, V. Masini, L. Deantonio, L. Aluffi Valletti, P. Sacchetti, G. Krengli, M. Radiat Oncol Research OBJECTIVE: To analyze the pattern of failure in relation to pre-treatment [(18)F] FDG-PET/CT uptake in head and neck squamous cell carcinoma (HNSCC) patients treated with definitive radio-chemotherapy (RT-CHT). METHODS AND MATERIALS: From 2012 to 2016, 87 HNSCC patients treated with definitive RT-CHT, with intensity modulated radiation therapy with simultaneous integrated boost, underwent pre-treatment [(18)F] FDG-PET/CT (PET(pre)), and MRI/CT for radiotherapy (RT) planning purposes. Patients with local recurrence, received [(18)F] FDG-PET/CT, (PET(rec)) at the time of the discovery of recurrence. In these patients, the metabolic target volume (MTV), MTV(pre) and MTV(rec) were segmented on PET images by means of an adaptive thresholding algorithm. The overlapping volume between MTV(pre) and MTV(rec) (MTV(pre&rec)) was generated and the dose coverage of MTV(rec) and MTV(pre&rec) was checked on the planning CT using the D99 and D95 dose metrics. The recurrent volume was defined as: ‘‘In-Field (IF)’’, “Marginal recurrence” or ‘‘Out-of-Field (OF)’’ if D95 was respectively equal or higher than 95%, D95 was between 95 and 20% or the D95 was less than 20% of prescribed dose. RESULTS: We found 10/87 patients (11.5%) who had recurrence at primary site. Mean MTV(pre) was 12.2 cc (4.6–28.9 cc), while the mean MTV(rec) was 4.3 cc (1.1–12.7 cc). Two recurrences resulted 100% inside MTV(pre), 4 recurrences were mostly inside (61–91%) and 4 recurrences were marginal to MTV(pre) (1–33%). At dosimetric analysis, five recurrences (50%) were IF, 4 (40%) marginal and one (10%) OF. The mean D99 of the overlapping volumes MTV(pre&rec) was 68.1 Gy (66.5–69.2 Gy), considering a prescription dose of 70 Gy to the planning target volume (PTV). CONCLUSION: Our study shows that the recurrence may originate from the volume with the highest FDG-signal. Tumor relapse in the high-dose volume support the hypothesis that an intensification of the dose on these volumes could be further assessed to prevent local relapse. BioMed Central 2021-03-21 /pmc/articles/PMC7981918/ /pubmed/33743759 http://dx.doi.org/10.1186/s13014-021-01787-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Pisani, C. Vigna, L. Mastroleo, F. Loi, G. Amisano, V. Masini, L. Deantonio, L. Aluffi Valletti, P. Sacchetti, G. Krengli, M. Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma |
title | Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma |
title_full | Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma |
title_fullStr | Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma |
title_full_unstemmed | Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma |
title_short | Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma |
title_sort | correlation of [(18)f] fdg-pet/ct with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981918/ https://www.ncbi.nlm.nih.gov/pubmed/33743759 http://dx.doi.org/10.1186/s13014-021-01787-5 |
work_keys_str_mv | AT pisanic correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma AT vignal correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma AT mastroleof correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma AT loig correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma AT amisanov correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma AT masinil correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma AT deantoniol correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma AT aluffivallettip correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma AT sacchettig correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma AT krenglim correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma |